Mark Thomas Email & Phone Number

Involved in the annotation of the human and mouse genomes, I have a particular interest in noncoding transcription. With expertise in genome interpretation, I currently support gene targeting activities at the Wellcome Sanger Institute.I joined the Wellcome Trust Sanger Institute in 2006, as a member of the Human and Vertebrate Analysis and Annotation (HAVANA) group. Undertaking gene annotation of the human and mouse genomes, I have gained considerable expertise in genome analysis, contributing towards the GENCODE gene set. I am particularly interested in the transcription of long noncoding RNAs, which despite their functional potential, remain poorly defined within the genome.Participating in the EUCOMM and KOMP high-throughput gene knockout programmes from an early stage, I have led the conditional design process, targeting the majority of mouse protein coding genes. I continue to be associated with the Stem Cell Engineering group at the Wellcome Sanger Institute, involved in both high-throughput targeting of human ES cells and the generation of bespoke mouse models using a range of CRISPR-Cas9 strategies.